Science & Enterprise subscription

Follow us on Twitter

  • Another way to connect 100 million people end-to-end with Covid-19 vaccines. https://t.co/wIWk0XNDhv
    about 14 hours ago
  • New post on Science and Enterprise: Celebrating the New Administration https://t.co/5ErPGhVDEN #Science #Business
    about 20 hours ago
  • A company applying Crispr gene-editing technology to treat inherited heart disease is raising $94 million in its se… https://t.co/2QgwrBLIQd
    about 2 days ago
  • New post on Science and Enterprise: Crispr Heart Disease Biotech Raises $94M in New Funds https://t.co/XJHC82ALY3 #Science #Business
    about 2 days ago
  • A vaccine protecting against multiple Covid-19 viral variations is in development, with an early-stage clinical tri… https://t.co/ZkSq0jOpmg
    about 2 days ago

Please share Science & Enterprise

Mobile Heart Monitor Algorithm Approved in Europe

AliveECG app

AliveECG app on an Android device (AliveCor Inc.)

22 January 2015. An algorithm analyzing signals to detect atrial fibrillation from a heart monitor built into mobile devices received regulatory approval in Europe. AliveCor, a developer of heart monitoring systems for mobile devices, says the company received the Conformité Européene or CE mark for the algorithm that analyzes heart monitoring signals in its AliveECG App.

The CE Mark signifies approval to market regulated products such as medical devices in the European Union and associated countries, but the company says the AliveECG app is now available only in the U.K. and Ireland. The AliveECG app analyzes signals from AliveCor’s heart monitor app to detect atrial fibrillation. If the heart rhythm pattern suggests atrial fibrillation, the AliveECG app notifies the user. The data, stored online, can also be shared with physicians.

The AliveCor heart monitor works with Apple/iOS and Android mobile devices, and is intended for use by physicians for patients with known or suspected heart conditions, as well as health-conscious patients. In August 2014, the Food and Drug Administration approved the AliveECG algorithm for use in AliveCor systems sold in the U.S.

Atrial fibrillation, or AFib, is an irregular heartbeat that can lead to stroke or heart failure, and affects some 2 million people in the U.K. and Ireland, as well as 2.7 million Americans. With AFib, heart muscle contractions in the upper chambers beat irregularly instead of in a regular rhythm, which can cause blood to pool and lead to blood clots, including those that move to the brain and cause a stroke. Some 15 to 20 percent of stroke victims have this kind of irregular heartbeat, and left untreated, people with AFib are 4 to 5 times more likely to suffer a stroke.

While some people with AFib report symptoms, such as a racing heartbeat or light-headedness, many people with the condition experience no symptoms, making it difficult to detect. AliveCor, in San Francisco, says the AliveECG app reports the condition in real time for quick action by patients and physicians, which can be particularly important for people who do not experience symptoms.

Beginning in June 2014, AliveCor established heart monitoring centers at pharmacies in the U.K. and Ireland , where store customers could test for atrial fibrillation with the company’s heart monitor app. Community screenings of this kind are important, says the company, since about one-third of cases with AFib have not yet been diagnosed.

Read more:

*     *     *

1 comment to Mobile Heart Monitor Algorithm Approved in Europe